Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eryaspase plus Chemotherapy in Advanced TNBC
NCT03674242Phase 3Terminated
- Sponsor
- PHAXIAM Therapeutics
- Start
- Jun 2019
- Primary completion
- Mar 2022
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of eryaspase in triple-negative breast cancer (TNBC), sponsored by PHAXIAM Therapeutics. Primary endpoint: Disease Control Rate at 1 year. Started Jun 2019; status: terminated.
02
Drugs
eryaspase
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03674242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674242.